# Decision Points for the 46th Board Meeting

## Master List

Version 10 November 2021

<table>
<thead>
<tr>
<th>#</th>
<th>Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Approval of the Rapporteur</td>
</tr>
<tr>
<td>2</td>
<td>Approval of the Agenda</td>
</tr>
<tr>
<td>3</td>
<td>Approval of the Strategy Narrative for the 2023-2028 Global Fund Strategy</td>
</tr>
<tr>
<td>4</td>
<td>Global Disease Split for the 2023-2025 Allocation Methodology</td>
</tr>
<tr>
<td>5</td>
<td>Amended Risk Appetite Statements</td>
</tr>
<tr>
<td>6</td>
<td>Independent Evaluation Function</td>
</tr>
<tr>
<td>7</td>
<td>2022 Work Plan and Budget Narrative and the 2022 Operating Expenses Budget</td>
</tr>
</tbody>
</table>
Decision Point GF/B46/DP01:

Gabriella Fesus from the European Commission, Belgium, Italy, Portugal, Spain Constituency is designated as Rapporteur for the 46th Board Meeting.

Signed:

Gabriella Fesus
Rapporteur

Fady Zeidan
Secretariat
Decision Point GF/B46/DP02:

The Agenda for the 46th Board Meeting (GF/B46/01_Rev1) is approved.

Signed:

Gabriella Fesus
Rapporteur

Fady Zeidan
Secretariat
Decision Point GF/B46/DP03:

Based on the recommendation of the Strategy Committee, as presented in GF/B46/03_rev1, the Board:

1. approves the Strategy Narrative for the 2023-2028 Global Fund Strategy in Annex 1 to GF/B46/03_rev1 and requests that the Secretariat develop, for presentation to the Strategy Committee in March 2022 and subsequently the Board in May 2022, an approach for Strategy implementation with a focus on delivering the key changes outlined in the Strategy using all existing levers and identifying where new solutions will be required; and

2. expresses its recognition to the Standing Committees for their work in the context of the development of the Strategy and looks forward to the continuous engagement between the Board, Secretariat and the Standing Committees, in line with their respective mandates, throughout the implementation of the Strategy.

**Budgetary implications:** The Secretariat will work with the Audit and Finance Committee on anticipated costing and operating expenses related to the Strategy once the Final Strategy is approved.

Signed:

_________________________________________  ___________________________
Gabriella Fesus                              Fady Zeidan
Rapporteur                                  Secretariat
Decision Point GF/B46/DP04:

Based on its review of the Secretariat’s analysis and recommendations on the global disease split for the 2023-2025 allocation period, and the Strategy Committee’s related deliberations, the Board:

1. Acknowledges that the total amount of funds available for country allocation (including approved sources of funds for country allocation and any additional funds approved as available for country allocation) will be decided by the Board in November 2022, based on the recommendation of the Audit and Finance Committee following announced replenishments results from the 7th Replenishment;

2. Approves that the apportionment of available country allocation funds across disease components (“Global Disease Split”) for the 2023-2025 allocation period will be determined by the total amount of available funds for country allocation for the 2023-2025 allocation period approved by the Board;

3. Acknowledging the increased share of deaths from tuberculosis among the three diseases, approves the following Global Disease Split for the 2023-2025 allocation period, which increases funding for tuberculosis while preserving funding and potential for scale-up for HIV and malaria:

   a. Any available funds for country allocation up to and including US$ 12 billion will be apportioned as follows: 50% for HIV/AIDS, 18% for tuberculosis, and 32% for malaria; and

   b. Any additional available funds for country allocation above US$ 12 billion will be apportioned as follows:

      i. 45% of such funds will be apportioned to HIV/AIDS;

      ii. 25% of such funds will be apportioned to tuberculosis; and

      iii. 30% of such funds will be apportioned to malaria.

4. Recognizing the need to further increase funding for tuberculosis and maximize the quality and impact of tuberculosis programs in line with the ambition of the Global Fund Strategy Narrative, requests the Secretariat, partners and committees, as relevant, to propose and implement specific options to address these needs, including:

   a. Presenting to the Board, at its 47th meeting, a proposal to leverage catalytic investments for the 2023-2025 allocation period to mobilize additional resources to reduce deaths from tuberculosis;
b. Aggressively exploring, on an ongoing basis, evidence-based portfolio optimization and prioritization opportunities in order to more effectively address tuberculosis incidence and mortality in high burden countries;

c. Continuing to pursue and monitor domestic co-financing commitments required to increase overall financing for tuberculosis; and

d. Continuing to pursue innovative finance opportunities to increase funding to tuberculosis in high burden countries.

5. Requests the Global Fund's Independent Evaluation Function to commission, in consultation with the Strategy Committee, technical partners and Secretariat, an external evaluation of the Global Fund’s approach to resource allocation to maximize impact, to inform evidence-based decision making on these issues ahead of the 8th replenishment, and to support more effective delivery of the Global Fund Strategy.

_Budgetary implications (included in, or additional to, OPEX budget): None._

Signed:

Gabriella Fesus
Rapporteur

Fady Zeidan
Secretariat
Amended Risk Appetite Statements

Decision Point GF/B46/DP05:

1. The Board:

   a. recalls its ultimate responsibility to the Global Fund’s stakeholders for overseeing the implementation of effective risk management;

   b. affirms the Strategy Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/SC17/14_Rev2 and pursuant to decision point GF/SC17/DP02;

   c. further affirms the Audit and Finance Committee’s concurrence with the amended Risk Appetite Statements under such committee’s oversight, as set forth in Annex 1 to GF/AFC17/02_Rev2 and pursuant to decision point GF/AFC17/DP02; and

   d. instructs the Secretariat to provide greater reporting on emerging risk trends and the effectiveness and results of the assurance measures, including the additional assurances put in place.

2. Based upon the recommendation of the Audit and Finance Committee, the Board approves the amended Risk Appetite Statements, including risk appetites, target risk levels and timeframes to achieve target risk, as set forth in Annex 1 to GF/B46/06, acknowledging that the target risk level for each risk shall become the revised risk appetite at the target due date.

3. This decision point and the amended Risk Appetite Statements approved by it shall supersede decision point GF/B39/DP11 (May 2018).

   **Budgetary implications (included in OPEX budget).**

Signed:

________________________________________________________________________
Gabriella Fesus                        Fady Zeidan
Rapporteur                            Secretariat
Decision Point GF/B46/DP06:

The Board notes the recommendation of the Strategy Committee and of the Ethics and Governance Committee, as set forth in GF/B46/05 rev1, with respect to the new independent evaluation model which shall replace the Technical Evaluation Reference Group ("TERG") and decides to approve the creation of the Independent Evaluation Panel, as described in GF/B46/05 rev1.

Accordingly, the Board:

1. Amends the Global Fund Bylaws, as set forth in Annex 1 of GF/B46/05 rev1, effective 31 December 2022;
2. Amends the Charter of the Strategy Committee, as set forth in Annex 2 of GF/B46/05 rev1, effective 31 December 2022;
3. Approves the Terms of Reference of the Independent Evaluation Panel ("IEP"), as set forth in Annex 3 of GF/B46/05 rev1 effective 31 December 2022, which will constitute one structure of the independent evaluation function previously held by the TERG, noting that approval of subsequent non-material modifications to this document are delegated to the Strategy Committee;
4. Requests the Secretariat, under the oversight of the relevant standing Committees, to update any policies, relevant governance documents, charters, terms of reference, agreements or prior decisions needed to align with the documents approved under paragraphs 1, 2 and 3 of this decision point and to manage the orderly transition between the Technical Evaluation Reference Group ("TERG") and the IEP;
5. Requests the Strategy Committee, in fulfilling its oversight role over the independent evaluation function, to consider the effectiveness of the guidance and procedures developed to safeguard both the independence and the learning components of the evaluation function; and
6. Decides to dissolve TERG following the transition period ending 31 December 2022 and instructs the Strategy Committee to develop and oversee transitional arrangement between the IEP and the TERG.

Budgetary implications (included in, or additional to, OPEX budget).

Signed:

___________________________   ___________________________
Gabriella Fesus      Fady Zeidan
Rapporteur       Secretariat
Decision Point GF/B46/DP07:

Based on the recommendation of the Audit and Finance Committee, the Board approves the:

1. 2022 Work Plan and Budget Narrative, as set forth in GF/B46/02; and

2. 2022 Operating Expenses Budget in the amount of US$ 322.2 million, as set forth in GF/B46/02 (the “2022 OPEX Budget”), which includes (i) US$ 65.5 million for in-country and external assurance activities, as described in GF/B46/02, and (ii) US$ 14.9 million for the Office of the Inspector General’s 2022 operating expenses.

Signed:

___________________________   ___________________________
Gabriella Fesus      Fady Zeidan
Rapporteur       Secretariat